Compare CBUS & NORD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CBUS | NORD |
|---|---|---|
| Founded | 2010 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Professional Services |
| Sector | Industrials | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 116.2M | 95.5M |
| IPO Year | 2017 | 2005 |
| Metric | CBUS | NORD |
|---|---|---|
| Price | $1.23 | $2.78 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | ★ 108.8K | 14.4K |
| Earning Date | 11-12-2026 | 11-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 74.33 | 31.25 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,639,000.00 | $3,346.00 |
| Revenue This Year | $39.09 | N/A |
| Revenue Next Year | $107.71 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.02 | $2.14 |
| 52 Week High | $4.19 | $5.28 |
| Indicator | CBUS | NORD |
|---|---|---|
| Relative Strength Index (RSI) | 45.80 | 25.62 |
| Support Level | N/A | $2.14 |
| Resistance Level | $1.65 | $3.31 |
| Average True Range (ATR) | 0.17 | 0.47 |
| MACD | 0.02 | -0.06 |
| Stochastic Oscillator | 42.58 | 28.51 |
Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.
Nordicus Partners Corp specializes in developing breakthrough therapeutics for diseases with unmet medical needs. The Company focuses on acquiring and developing drugs from biotech companies in the Nordics, a region known for its scientists, life sciences ecosystem, and drug discoveries and developments. Its current portfolio includes the preclinical biotechnology companies Orocidin A/S, Bio-Convert A/S, and NoviThera ApS. The Company is dedicated to developing breakthrough therapeutics in diseases with unmet medical needs, starting with oral disorders. It operates in the segment focused on developing medicines supporting oral health.